Drug recall · April 11, 2018
buPROPion HCl Extended-Release Tablets recall
Why: Failed Dissolution Specifications; during stability testing
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 60 count bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788 --- NDC 69097-877-03
- Lots / codes
Lot# I1606579 and Lot# I1606580 Exp: 05/2018; Lot# I1612114 and Lot# I1612115 Exp: 11/2018
- Quantity
- N/A
- Company
- InvaGen Pharmaceuticals, Inc., Hauppauge, NY
- Distribution
- Nationwide
- Initiated
- March 15, 2018 · Voluntary: Firm initiated
- Classified
- April 4, 2018
- Reported
- April 11, 2018
- Ended
- September 15, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.